Is BPC-157 legal in 2026?
A dated, plain-English answer — and what a licensed clinician can prescribe today while BPC-157 sits in front of the FDA.
Last reviewed July 14, 2026 · Updated after every FDA action · Not legal or medical advice
Short answer
BPC-157 is not FDA-approved for any human use. It is not on the FDA's 503A Bulks List — the list that lets a licensed pharmacy compound a substance for patients.
In April 2026 the FDA removed BPC-157 from Category 2. That lifted an earlier restriction. It is not the same as approval, and it did not authorize compounding.
Its status is under review at an FDA advisory meeting on July 23–24, 2026. Until the FDA acts through formal rulemaking, there is no compliant way to prescribe it — and any site selling injectable BPC-157 for human use today is operating outside the regulated pathway.
The two signals, kept separate
We keep these two signals separate on purpose. The regulatory label and the plain-English verdict answer different questions — and collapsing them is how gray-market sites make "removed from Category 2" sound like "cleared to buy."
Why the answer isn't yes or no
"Legal" means three different things, and BPC-157 fails all three
Most of the confusion online comes from mixing these up. They're separate questions with separate answers.
"Is it FDA-approved?"
No. BPC-157 has never been approved by the FDA for any human indication. Approval means the FDA reviewed the drug for safety and effectiveness. That has not happened, and nothing in 2026 changed it.
"Can a pharmacy compound it?"
Not compliantly. A pharmacy needs one of three things: a USP monograph, status as a component of an FDA-approved drug, or a place on the 503A Bulks List. BPC-157 has none of them. That's what the July meeting is about.
"Is it banned?"
No — and this is the part vendors exploit. Removal from Category 2 in April 2026 lifted a restriction. It did not grant permission. "Not prohibited" and "authorized" are not the same thing, and the gap between them is exactly where the gray market sells.
What the FDA is actually weighing, and what each outcome would mean →
Where BPC-157 stands — and what's available today
Two signals, kept separate: the regulatory status, and what it means for you.
See the full tracker and the changelog →
Compounded, not FDA-approved. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not reviewed by the FDA for safety, effectiveness, or manufacturing the way approved drugs are. They are not the same as brand-name products, and they're only appropriate when a licensed clinician determines FDA-approved options don't fit your situation.
What we'll do when the FDA acts
We update this page within a day of any FDA action and date every change, so you can check when we last looked. We won't market BPC-157 until a licensed clinician can prescribe it through a compliant pharmacy — whatever the committee recommends.
The July 23–24 agenda, and the coverage we'll post →
Here's what a clinician can help with today
If you came here for recovery, energy, longevity or weight, you don't have to wait on a committee. There are compounded therapies a licensed clinician can prescribe today where they're clinically appropriate — matched to your goal, your health history and your state. Two minutes tells you what you're eligible for. Nothing to pay to find out.
Questions people ask
Is BPC-157 legal in 2026?
BPC-157 is not FDA-approved for any human use, and it is not on the FDA's 503A Bulks List that would let licensed pharmacies compound it. In April 2026 the FDA removed it from Category 2 — lifting a prior restriction without authorizing compounding. Its status is under review at the July 23–24 PCAC meeting. Until the FDA acts through rulemaking, there is no compliant prescribing pathway.
Did the FDA ban BPC-157?
No. Removal from Category 2 is neither a ban nor approval. It means an earlier prohibition was lifted while the FDA reviews whether to add the substance to the 503A list. The July meeting produces a recommendation only; the FDA makes the final call afterward through a formal rulemaking process.
Can I buy BPC-157 from Peptos?
No. We publish education and a waitlist only. We won't market or facilitate a prescription for BPC-157 until a licensed clinician can prescribe it through a compliant pharmacy. If a site offers to ship you injectable BPC-157 for human use today, it's operating outside the regulated pathway — and the product quality is unverified.
What about sites selling BPC-157 as "research use only"?
Research-use-only products are sold for laboratory work, without a prescription, a clinician, or medical oversight. When a vendor sells an RUO vial and then supplies human dosing guidance, the label is doing legal work the product isn't. Independent testing of research peptides has repeatedly found underdosed, contaminated, or misidentified product. We break the distinction down in full on our peptide legality guide.
Why are CJC-1295 and Ipamorelin marked "not available"?
Both have been outside the compounding pathway since the 2023 Category 2 action and are not on the 503A list. We don't list them as available, and we treat any vendor presenting them as ready-to-order as a signal to look elsewhere.
What can a clinician prescribe right now?
Depending on your health history and your state, a licensed clinician may prescribe compounded semaglutide or tirzepatide, sermorelin, NAD+ and B12, among others. These are compounded and not FDA-approved. The eligibility check shows what applies to you before anyone charges you anything.